Search results (13)
« Back to NewsThe latest news, stories and exciting findings from across the Oxford cancer research community
Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene
29 September 2022
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.
How Oxford has shaped cancer science
4 February 2022
As part of World Cancer Day 2022 we are diving into 10 of Oxford’s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.
First patient dosed with lung cancer immunotherapy vaccine
18 January 2022
The first patient has been dosed in the MAGE trial, which is testing a novel immunotherapeutic known as VTP-600, in patients with the most common type of lung cancer.
MP Anneliese Dodds tours Oxford cancer research
26 November 2021
Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.
World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition
23 November 2021
Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.
FOCUS4: a flagship trial in colorectal cancer
20 September 2021
Professor Tim Maughan outlines the flagship work of the FOCUS4 trials, whose results were presented this weekend at the European Society of Medical Oncology (ESMO) annual meeting
Study investigating targeted drug delivery by focused ultrasound for pancreatic cancer opens
2 July 2021
University of Oxford researchers have begun recruitment to a study looking at whether chemotherapy medication can reach pancreatic tumours more effectively if encapsulated within a heat-sensitive shell and triggered with focused ultrasound.
Groundbreaking FOCUS4 clinical trials report their findings at ASCO
8 June 2021
Principal Investigator Tim Maughan talks about the forward-thinking approach of the FOCUS4 cancer clinical trials and how they have helped shape the UK's fight against COVID-19
Oxford spin out financed $6.8m for research into oncolytic therapies
7 January 2021
Oxford spin out company Theolytics has closed a $6.8m deal to support their work into developing novel cancer therapies from viruses
Being a part of cancer drug discoveries
17 December 2020
Susan Cakebread, gives her account of being on the Tebentafusp experimental immunotherapy drug trial in 2014. A Phase 1 trial for melanoma that began here in Oxford, and is now entering Phase 3 trials after giving Susan back her life.
SCALOP team discover new pancreatic cancer biomarker
27 November 2020
The SCALOP clinical trial team have uncovered a new therapeutic target for locally advanced pancreatic cancer. Read more about it and the next steps for the SCALOP-2 trial.
Innovative drug delivery techniques show promise in clinical trials
2 November 2020
Dr Laura Spiers talks about the TarDox and PanDox trials, which are using novel drug delivery techniques to improve the uptake of chemotherapy drugs into pancreatic tumours and other cancers
Funding boost for OxPLoreD early detection study
20 October 2020
UK Research and Innovation provides additional funds for whole genome sequencing as part of the OxPLoreD programme of research into high-risk conditions for blood cancer